Eli Lilly Enters $415M Licensing Deal with Alchemab for ATLX-1282 in Neurodegenerative Diseases

May 06, 2025 17:07 CST Updated 17:07

Alchemab Therapeutics

Biological New Drug Developer

Eli Lilly

Global Pharmaceutical R&D and Production Company

On May 6 local time, Alchemab Therapeutics announced that it hasEli LillyLicense Agreement Reached for ATLX-1282, Alchemab's Candidate for Amyotrophic Lateral Sclerosis（ALS）And other innovative candidate drugs developed for neurodegenerative diseases.

Screenshot source: Corporate official website

The total value of this transaction is up to$4.15 billion, including undisclosed upfront payments, potential discovery, development and commercialization milestone payments, as well as royalties.

Under the terms of the agreement, Alchemab will be responsible for the early Phase I clinical trial of the project, after which Eli Lilly will lead all further development and commercialization efforts.

ATLX-1282 is a product developed by Alchemab TherapeuticsMachine Learning and Artificial IntelligenceA unique platform for technology developmentFirst Project, the platform can sequence and analyze millions of antibody sequences, thereby discovering novel targets and antibodies with unique mechanisms of action.

It is worth mentioning that this agreement is based on the cooperation agreement reached between Alchemab and Eli Lilly in January 2025. In January 2025, Alchemab announced an agreement with Eli Lilly. According to the terms of the agreement, Alchemab will collaborate with Eli Lilly to discover, develop, and commercializeUp to Five Novel Candidate Therapies for Treating ALS。

Scan the WeChat QR code, add the editor of Antibody Circle, and those who meet the requirements can join the Antibody Circle WeChat group!
Please indicate: Name + Research Direction!

All reproduced articles in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reproduced can contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the author and do not represent the position of this site.